Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2018: PRESS-RELEASE: Paris  July17, 2018: World's first: The French Chronic Fatigue Syndrome Association decides to clinically evaluate the ME/CFS pathogenesis model produced by Bio-Modeling Systems

  • 2018: ANNOUNCEMENT: Paris May 28, 2018 Bio-Modeling Systems est heureuse de vous informer sur ses interventions lors des conférences suivantes

  • 2018: ANNOUNCEMENT: Paris June 19-20, 2018: BMSystems invited to the Micorbiotes conference organised by Adebiotech to present its microbiota vision and CADI Discovery programs 

  • 2018: ANNOUNCEMENT: Paris June 14, 2018: BMSystems invited to the Connected Health Conference organised by ANRT to present its Real life data strategy with its "patients & HCP digital pathways" partner Bolero

  • 2018: ANNOUNCEMENT: Paris March 13-14, 2018: BMSystems invited to the Epigentic conference organised by Adebiotech to present its CADI Discovery program EPIGEN-DIAB with the Centrer of excelllence in Eipgenetic in India

  • 2017: PRESS-RELEASE: Paris-November 16, 2017: BMSystems is selected to pitch at the “Translational Neurosciences Conference” organized by “NeurATRIS” and supported by “eartis” the European Infrastructure For Translational Medicine, comprising more than 80 leading European Institutes.

  • 2017: PRESS-RELEASE: Paris-New-York October 4, 2017: BMSystems, with its 14 independently validated successes to date, is selected by the Galien Foundation for the MedStartUp Award 2017 program first step during the US Galien Prize Forum in New-York.
     
  • 2017: ANNOUNCEMENT: Latest news:  Press-release from Hospices Civils de Lyon about phage therapy success with Pherecydes Pharma bacteriophages. Pherecydes-Pharma, is BMSystems’ first therapeutic spin-off.
     

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

"Correct understanding of diseases / disorders mechanisms is the first objective. Finding the most adapted integrated diagnostics, therapies & preventive solutions are the necessary consequences of the first objective".

Bio-Modeling Systems is the world’s first Mechanisms-Based Medicine company that changed the discovery paradigm to create novel robust medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™* models.

We propose to R&D & Translational Medicine Executives, robust alternative decision-making to de-risk, save time, costs, and novel cost-effective diagnostics/therapies for their businesses.

Created in 2004, profitable since 2006, thanks to our recurrent clients, we confirmed in Pharma, Biotech, Cosmetics, Nutrition and digital-Health, CADI™ Discovery capability to achieve:

  1. A world's first in neurodegenerative diseases (publication) with CEA: 2 awards in the US & Europe.

  2. Pherecydes-Pharma: BMSystems' spin-off, MR infections therapies,  3 patents, publication, world's first multi-centric clinical trial with bacteriophages in Phase I/II, Compassionate Use Success.

  3. CEA/BMSystems collaborative research in CNS that led to the co-owned patent WO201029131 with a worldwide exclusive license to Theranexus, CEA’s spin-off currently in Phase II, and

  4. 14 CADI™ successes independently validated by our clients/partners.

We warmly invite you to download our management summary,  our Short corporate Presentation or our CADI™ Discovery Concept and POCs Presentation.

 

The life-modeling issue: Are we using the right concepts in the righ order?

 

CADI™ : Computer Assisted Deductive Integration Rational